Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Soricimed Biopharma has treated first patient in Phase I trial of anti-cancer agent, SOR-C13, at the Juravinski Cancer Centre in Hamilton, Ontario, Canada.
Subscribe to our email newsletter
The multicentre, open-label study is designed to assess safety and tolerability of SOR-C13, in addition to pharmacokinetics, biomarkers and initial evidence for efficacy.
Soricimed Biopharma chairman and chief scientific officer Jack Stewart said unlike chemotherapy, the company’s cancer treatment is highly targeted – affecting only cancer cells.
"Healthy cells are not affected. It’s also a biologic, meaning it’s derived from a naturally occurring peptide that when broken down produces amino acids that can be reused by the body," Stewart added.
"As a result, and this is key, there have been virtually no side effects demonstrated in our pre-clinical studies."
The company expects to carry out Phase I trials till February 2013 and to release interim results later in 2012. Based on successful results, further clinical trials will follow.